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Targeted proteolysis of endogenous proteins is desirable as a research toolkit
and in therapeutics. CRISPR/Cas9-mediated gene knockouts are irreversible
and often not feasible for many genes. Similarly, RNA interference approaches
necessitate prolonged treatments, can lead to incomplete knockdowns and are
often associated with off-target effects. Targeted proteolysis can overcome
these limitations. In this report, we describe an affinity-directed proteinmissile
(AdPROM) system that harbours the von Hippel–Lindau (VHL) protein, the
substrate receptor of the Cullin2 (CUL2) E3 ligase complex, tethered to poly-
peptide binders that selectively bind and recruit endogenous target proteins
to the CUL2-E3 ligase complex for ubiquitination and proteasomal degra-
dation. By using synthetic monobodies that selectively bind the protein
tyrosine phosphatase SHP2 and a camelid-derived VHH nanobody that selec-
tively binds the human ASC protein, we demonstrate highly efficient
AdPROM-mediated degradation of endogenous SHP2 and ASC in human
cell lines. We show that AdPROM-mediated loss of SHP2 in cells impacts
SHP2 biology. This study demonstrates for the first time that small polypep-
tide binders that selectively recognize endogenous target proteins can be
exploited for AdPROM-mediated destruction of the target proteins.
1. Introduction
Achieving targetedproteolysis of endogenous cellular proteins is not onlydesirable
for research into their function, but is increasingly sought after as an approach to
disrupt target protein function in therapeutics. The ubiquitin–proteasome system
(UPS) is amajorplayer for theproteolysis ofmany cellular proteins formaintenance
of homeostasis [1–3]. Through sequential actions of the E1 ubiquitin-activating
enzyme, E2 ubiquitin-conjugating enzymes and E3 ubiquitin ligases, target pro-
teins are covalently labelled with ubiquitin chains, marking them for recognition
and destruction by the proteasome [4,5]. The Cullin RING (really interesting new
gene) E3 ligase (CRL) family represents one of the key contributors to the UPS
for protein turnover in cells [6,7]. Each CRL complex comprises one Cullin
(CUL1-7) member, one or more adaptors that bind to a substrate receptor and a
RING E3 ligase (RBX1/2) [6,7]. For example, the CUL2-CRL is in a complex with
ElonginBandCasadaptors, thevonHippel–Lindau (VHL)proteinas thesubstrate
receptor, and RING-box protein 1 (RBX1) as the E3 ligase [8,9]. All CRLs are acti-
vated through the covalent attachment of the small ubiquitin-like modifier
NEDD8 to lysine residues of the Cullin (a process termed NEDDylation [10]),
and the pan-Cullin NEDDylation inhibitor MLN4924 inhibits CRL activation [11].
By combining the CUL2 machinery and anti-GFP nanobodies (aGFP), we
recently reported an efficient affinity-directed protein missile (AdPROM)
system for proteolysis of endogenous target proteins that were marked by knock-
ing in a GFP-tag using CRISPR/Cas9. This AdPROM system was engineered
with the CUL2 substrate receptor VHL tethered to aGFP [12]. The efficacy of
& 2017 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
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this proteolytic AdPROM suggested that this technology could
be applied to achieve degradation of endogenous proteins by
simply replacing the aGFP with small polypeptide binders
that specifically recognize endogenous target proteins. Recent
advances in polypeptide binder technologies have greatly
expedited the development of highly selective, high-affinity
polypeptide interactors of proteins [13,14]. One approach
frequently employed to derive such polypeptide binders
involves isolating single domainVHHantibodies (nanobodies)
from camelid species, such as llama and alpaca, after immuniz-
ation with protein antigens [15]. Nanobodies recognizing GFP
and the human protein Apoptosis-associated speck-like
protein containing CARD (ASC) are examples of camelid-
derived nanobodies [15,16]. A second method exploits a
synthetic approach, typically using a b-sandwich protein
based on the 10th human fibronectin type III domain as a back-
bone, where varying combinations of residues in the variable
regions are screened for high-affinity interactions with target
proteins. These are referred to as monobodies [14]. A series of
monobodies selectively recognizing the Src-homology 2 (SH2)
domain-containing phosphatase 2 (SHP2) (also known as
PTPN11) and the non-receptor tyrosine protein kinase Abl
were developed using this synthetic screening approach [17,18].
In this study, we explore the efficacy of the AdPROM
system to degrade endogenous SHP2 and ASC across different
cell lines using their cognate mono/nanobodies as affinity
probes. SHP2 is a non-receptor tyrosine phosphatase that is
ubiquitously expressed in vertebrate cells and tissues [19].
SHP2 possesses two SH2 domains, termed N-SH2 and
C-SH2, and a protein tyrosine phosphatase (PTP) domain.
Activating mutations in SHP2 have been reported in multiple
pathologies, including Noonan syndrome, juvenile myelo-
monocytic leukaemia, and lung and breast cancers [20].
SHP2 is reported to play a major role in mediating Ras/
MAPK signalling, although this role appears to be context-
specific [21]. The precise role of SHP2 phosphatase activity in
MAPK signalling is not fully elucidated, in part because very
few substrates of SHP2 are known. SHP2 has been reported
to mediate transformation of cells, and modulate MAPK and
signal transducer and activator of transcription 3/5 (STAT3/
5), signalling downstream of the breakpoint cluster region
(BCR)-Abl fusion protein, which occurs frequently in chronic
myelogenous leukaemia (CML) as a result of a chromosomal
translocation event [22–28]. While small-molecule tyrosine
kinase inhibitors (TKIs) of BCR-Abl, such as Imatinib, have
hadgreat success in the clinic, acquired drug resistance remains
a problem in treating CML effectively [29]. As such, SHP2 has
been considered a useful therapeutic target and the mono-
bodies recognizing SHP2 (used in this study) were reported
to inhibit MAPK signalling driven by BCR-Abl overexpression
[17]. More recently, an allosteric inhibitor of SHP2, SHP099,
was also reported to inhibit proliferation andMAPK signalling
in cancers driven by receptor tyrosine kinases (RTKs) [21].
ASC is a key commonadaptor of all inflammasomes,which
are key signalling platforms in myeloid cells that detect infec-
tions and cell damage. Inflammasomes enable the production
of pro-inflammatory cytokines IL-1b and IL-18, as well as cell
death by pyroptosis [30,31]. ASC knockout mice exhibit
reduced levels of pro-inflammatory cytokines in the serum,
while bonemarrow-derivedmacrophages from thesemice dis-
play defective inflammasome signalling [32]. Overexpression
of the nanobody recognizing human ASC has been shown to
impair inflammasome assembly and signalling [16].
Equippedwith small polypeptidemonobodies recognizing
SHP2 and a nanobody recognizing human ASC protein, we
sought to test whether the proteolytic AdPROM system,
consisting of VHL conjugated to these mono/nanobodies,
was capable of degrading endogenous SHP2 and ASC via the
proteasome across different cell lines. In this study, we show
for the first time that the proteolytic AdPROM system can be
engineered with selective mono/nanobodies recognizing
endogenous target proteins to efficiently degrade the target
protein in many cell types.
2. Results
2.1. Proteolytic AdPROM degrades endogenous SHP2
in multiple human cancer cell lines
In an attempt to test whether the proteolytic AdPROM consist-
ing of VHL tethered to monobodies recognizing human SHP2
could degrade endogenous SHP2, we employed two distinct
monobodies that selectively bind the N-SH2 and C-SH2
domains of SHP2, termed aNSa1 (KD ¼ 14 nM) and aCS3
(KD ¼ 4 nM), respectively [17] (figure 1a,b). VHL-aNSa1 and
VHL-aCS3 were packaged in mammalian expression
pBABE retroviral vectors, with an in-frame FLAG tag at
the N-terminus for monitoring AdPROM expression. We
infected U2OS osteosarcoma, MDA-MB-468 mammary gland
adenocarcinoma, A549 pulmonary adenocarcinoma and
MDA-MB-231 breast cancer cells with retroviruses encoding
the expression of VHL, aNSa1, VHL-aNSa1, aCS3 or
VHL-aCS3, and monitored the endogenous SHP2 levels
(figure 1c–f ). The endogenous SHP2 levels were comparable
and unaltered in uninfected cells and cells infected with
VHL, aNSa1, or aCS3 controls (figure 1c–f ). By contrast, com-
pared with these control cells, we observed a substantial
reduction in endogenous SHP2 protein levels upon expression
of VHL-aNSa1 (figure 1c–f ). Strikingly, no detectable SHP2
protein levels were observed in any of the cell lines when
VHL-aCS3 was expressed in cells (figure 1c–f). This reduction
in SHP2 protein levels is unlikely to be due to a decrease in
SHP2 mRNA transcripts, as cells infected with VHL-aCS3
appeared to express slightly higher levels of SHP2 transcripts
compared with the control cells (electronic supplementary
material, figure S1). Collectively, the results suggest that the
VHL-aCS3 AdPROM results in complete proteolysis of
endogenous SHP2 in multiple human cancer cell lines.
2.2. Proteolytic AdPROM uses CUL2-CRL for SHP2
destruction
To demonstrate that degradation of SHP2 by VHL-aNSa1 and
VHL-aCS3 occurs via the predicted CUL2-CRL machinery, we
used the selective Cullin NEDDylation inhibitor MLN4924 in
U2OS cells. In uninfected wild-type U2OS cells or control
cells infected with aCS3, we observed no notable changes in
levels of endogenous SHP2 protein following treatment of
cells with MLN4924 for 6 or 24 h (figure 2a). By contrast, the
degradation of endogenous SHP2 caused by VHL-aCS3 was
rescued in a time-dependent manner following MLN4924
treatment, with a robust rescue observed at 24 h (figure 2a).
Analogous rescue of SHP2 protein levels by MLN4924 treat-
ment was observed in U2OS cells infected with VHL-aNSa1
rsob.royalsocietypublishing.org
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AdPROM (electronic supplementary material, figure S2a).
Consistent with the key role of the CUL2-CRL machinery in
controlling hypoxia-inducible factor 1-alpha (HIF1a) protein
stability, treatment of cells with MLN4924 resulted in stabiliz-
ation of HIF1a at both 6 h and 24 h time points (figure 2a;
electronic supplementary material, figure S2a). Infection of
cells with any of aCS3, VHL-aCS3, aNSa1 and VHL-aNSa1
did not result in changes in HIF1a protein levels (figure 2a;
electronic supplementary material, figure S2a), suggesting
that the expression of the AdPROM system does not interfere
with hypoxia signalling.
Next, we sought to verify the interaction between the
monobodies and the endogenous SHP2 in cell extracts. We
performed anti-FLAG immunoprecipitations (IPs) from
extracts of wild-type U2OS cells or those infected with
FLAG-aCS3 or FLAG-VHL-aCS3 and treated with or without
MLN4924 (figure 2b). FLAG-aCS3 IPs robustly precipitated
endogenous SHP2, irrespective of MLN4924 treatment,
while control anti-FLAG IPs from wild-type U2OS extracts
did not pull down SHP2 (figure 2b). By contrast, in the
absence of MLN4924 treatment, FLAG-VHL-aCS3 IPs did
not precipitate detectable levels of endogenous SHP2, while
following MLN4924 treatment some endogenous SHP2 was
detected (figure 2b). These observations simply reflect the
levels of endogenous SHP2 detected in extracts of cells
infected with FLAG-VHL-aCS3 (figure 2). Analogous results
were observed when cells were infected with FLAG-aNSa1
and FLAG-VHL-aNSa1 (electronic supplementary material,
figure S2b). Collectively, these results highlight the affinity
of aNSa1 and aCS3 for endogenous SHP2 and suggest that
the proteolytic AdPROM-mediated degradation of SHP2 is
mediated by the VHL-CUL2 machinery.
2.3. SHP2 destruction causes partial attenuation
of ERK1/2 phosphorylation
SHP2 activity has been reported to regulate Ras/MAPK
signalling [17,33]. In order to evaluate the impact of
AdPROM-mediated proteolysis of SHP2 in cells, we assessed
the levels of basal and epidermal growth factor (EGF)-
induced phosphorylation of ERK1/2 (also referred to as
p44/p42 MAPK) in U2OS and MDA-MB-468 cells. First, we
performed a time course experiment for EGF stimulation in
wild-type U2OS cells or cells infected with either aCS3 or
VHL-aCS3. In wild-type cells, EGF induced a peak ERK1/2
phosphorylation at Thr202 and Tyr204 residues between
15 and 60 min, which diminished after 120 min of EGF
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Figure 1. Proteolytic AdPROM degrades endogenous SHP2 in multiple human cancer cells. (a) Domain structure of SHP2. N-SH2, N-terminal SH2 domain; C-SH2,
C-terminal SH2 domain; PTP, protein tyrosine phosphatase. The monobodies aNSa1 and aCS3 recognize the N-SH2 and C-SH2 domains, respectively. (b) Schematic
describing the concept of AdPROM-mediated target protein degradation using monobodies or nanobodies to recruit endogenous target proteins. For example, VHL
conjugated to SHP2 monobody recruits endogenous SHP2 protein to the EloB/C/CUL2/RBX1 E3 ligase machinery for ubiquitin-mediated proteasomal degradation.
(c– f ) Human U2OS osteosarcoma (c), MDA-MB-468 mammary gland adenocarcinoma (d ), A549 lung cancer (e) and MDA-MB-231 breast cancer ( f ) cells were
infected with retroviruses encoding FLAG-VHL-aNSa1 or FLAG-VHL-aCS3 or controls (VHL alone, FLAG-aNSa1 alone and FLAG-aCS3 alone) as indicated or left unin-
fected (WT). Cell extracts (20 mg protein) were resolved by SDS-PAGE and transferred to PVDF membranes, which were subjected to western blotting with the
indicated antibodies.
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treatment (figure 3a). Expression of aCS3 alone, which binds
the C-SH2 domain of SHP2 and inhibits it allosterically [17]
anddoes not cause SHP2degradation, caused partial reduction
in levels of EGF-induced phospho-ERK1/2 at all time points
tested (figure 3a). Similarly, VHL-aCS3 expression, which
caused complete loss of SHP2 protein, also caused partial
reduction in levels of EGF-induced phospho-ERK1/2 at all
time points tested (figure 3a). Both aCS3 and VHL-aCS3
expression caused complete loss of SHP2 phosphorylation at
Tyr580 (figure 3a). These results suggest that both occluding
the C-SH2 domain of SHP2 by aCS3 monobody and the
loss of SHP2 protein both equally impact EGF-induced
phosphorylation of ERK1/2 in U2OS cells. By contrast, in
MDA-MB-468 cells in which SHP2 has been reported to med-
iate Ras/MAPK signalling downstream of receptor tyrosine
kinases, only destruction of SHP2 byVHL-aCS3 caused amod-
erate reduction in EGF-induced phospho-ERK1/2 levels, while
the expression of VHL, aNSa1, VHL-aNSa1 or aCS3 alone did
not significantly impact EGF-induced phospho-ERK1/2 levels
or SHP2 phosphorylation at Tyr580 (figure 3b).
Activation of Ras/MAPK signalling downstream of the
constitutively active BCR-Abl tyrosine kinase has been
reported to require SHP2 activity [17]. To investigate the effects
of AdPROM-mediated SHP2 degradation in the context of
BCR-Abl-induced Ras/MAPK signalling, we transfected the
BCR-Abl fusion gene intowild-typeU2OS cells or cells infected
with aNSa1, VHL-aNSa1, aCS3 or VHL-aCS3, and monitored
levels of phospho-ERK1/2. In wild-type control cells, BCR-
Abl expression resulted in robust SHP2 phosphorylation on
Tyr580, a known c-Abl phosphorylation site on SHP2 [34],
and phosphorylation of ERK1/2 (figure 3c). Treatment of
cells with Imatinib, the BCR-Abl tyrosine kinase inhibitor,
completely abolished phosphorylation of SHP2 on Tyr580,
STAT3 on Tyr705 and STAT5 on Tyr694 [31–34], but did not
significantly impact BCR-Abl-induced phospho-ERK1/2
levels (figure 3c). In cells infected with aNSa1, VHL-aNSa1
and aCS3, the BCR-Abl-induced phosphorylation of ERK1/2
was not significantly different from wild-type U2OS cells
(figure 3c). However, in cells infected with VHL-aCS3, which
caused complete degradation of SHP2, BCR-Abl-induced
phospho-ERK1/2 levels were slightly attenuated compared
withwild-type and aCS3 alone controls (figure 3c). As reported
previously [17], aNSa1 and aCS3 expression caused reduction
in SHP2 phosphorylation on Tyr580, suggesting that the inter-
actions between these monobodies and SHP2 potentially
obstruct the BCR-Abl-induced phosphorylation of SHP2
(figure 3c). The phosphorylation of SHP2 was undetectable
in cells infected with VHL-aCS3, as there was no detectable
level of the total SHP2 protein (figure 3c). The infection of
cells with aNSa1, VHL-aNSa1, aCS3 and VHL-aCS3 did not
alter the levels of phospho-STAT3-Tyr705 or phospho-STAT5-
Tyr694 (figure 3c). Compared with WT cells or cells infected
with VHL, aNSa1 and VHL-aNSa1, infection of cells with
aCS3 and VHL-aCS3 caused a reduction in BCR-Abl-induced
total phospho-Tyr levels (figure 3c). Similarly, Imatinib treat-
ment also caused reduction in BCR-Abl-induced total
phospho-Tyr levels (figure 3c).
We also tested the effects of AdPROM-mediated SHP2
degradation on MAPK signalling in K-562 chronic myelogen-
ous leukaemia cells, which naturally harbour the BCR-Abl
fusion (figure 3d ). We infected K-562 cells with retroviruses
encoding the expression of VHL, aNSa1, VHL-aNSa1, aCS3
or VHL-aCS3, treated them with or without the BCR-Abl
tyrosine kinase inhibitor Imatinib, and monitored the SHP2
and phospho-ERK1/2 levels (figure 3d ). The endogenous
SHP2 levels were comparable and unaltered in uninfected
cells or cells infected with VHL, aNSa1 or aCS3 controls.
By contrast, compared with these control cells, we observed
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Figure 2. Proteolytic AdPROM employs CUL2-CRL for SHP2 destruction. (a) Uninfected U2OS cells (WT) or cells infected with retroviruses encoding FLAG-VHL-aCS3 or
control viruses (FLAG-aCS3 alone) were treated with MLN4924 (1 mM) for 0, 6 or 24 h. Cells were lysed and extracts (20 mg protein) were resolved by SDS-PAGE
and transferred to PVDF membranes, which were subjected to western blotting with the indicated antibodies. HIF1a serves as a positive control for MLN4924
treatment. (b) U2OS cells treated with or without MLN4924 (1 mM) for 24 h were lysed and extracts (1 mg protein) subjected to immunoprecipitation (IP)
with anti-FLAG M2 resins. Following elution, both IPs and input extracts (20 mg protein) were resolved by SDS-PAGE and transferred to PVDF membranes,
which were subjected to western blotting with the indicated antibodies.
rsob.royalsocietypublishing.org
Open
Biol.7:170066
4
 on May 16, 2017http://rsob.royalsocietypublishing.org/Downloaded from 
a slight reduction in endogenous SHP2 protein levels upon
expression of VHL-aNSa1, but a substantial reduction upon
VHL-aCS3 expression (figure 3d ). Under these conditions,
in the absence of Imatinib the levels of phospho-ERK1/2
did not change substantially (figure 3d ). By contrast, treat-
ment of cells with Imatinib caused complete inhibition of
phospho-ERK1/2 and phospho-STAT5 levels, both of which
are known to be induced by BCR-Abl [17,22,24,25,28]
(figure 3d ). Collectively, these observations suggest that the
role of SHP2 in Ras/MAPK signalling is perhaps limited in
nature and may be context-specific.
2.4. Comparing the effects of SHP2 degradation and
allosteric inhibition on Ras/MAPK signalling
The context-dependent effects of SHP2 in Ras/MAPK signal-
ling were illustrated in a recent report in which a selective
allosteric inhibitor of SHP2, termed SHP099, was shown to
block the activation of ERK1/2 downstream of RTKs in certain
cell types [21]. We treated a number of cell lines with varying
doses of SHP099 to assess the impact of SHP2 inhibition on
ERK1/2 phosphorylation (figure 4a). We observed that
SHP099 caused an efficient, dose-dependent inhibition of
ERK1/2 phosphorylation in U2OS, K-562 and MDA-MB-468
cells, but not an efficient inhibition in A549 cells (figure 4a).
It should be noted that the relative levels of SHP2 in U2OS
and A549 cells were higher than K-562 and MDA-MB-468 cells
when normalized against the total protein concentration in
extracts (figure 4a). In order to investigatewhether the inhibition
of ERK1/2 phosphorylation by SHP099 is mediated through
SHP2, we tested the impact of AdPROM-mediated degradation
of SHP2 in U2OS cells treated with or without SHP099
(figure 4b). In wild-type U2OS cells, basal phospho-ERK1/2
levels were completely inhibited by SHP099 (figure 4b).
Compared with the wild-type cells, no significant changes in
the levels of phospho-ERK1/2 were observed in U2OS cells
infectedwith VHL, aCS3 or VHL-aCS3, which caused complete
degradation of endogenous SHP2 but not SHP1 (figure 4b). In
cells infected with VHL-aCS3, SHP099 still resulted in complete
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Figure 3. SHP2 destruction causes partial attenuation of ERK1/2 phosphorylation. (a) Wild-type, uninfected U2OS cells or cells infected with FLAG-aCS3 and
FLAG-VHL-aCS3 were treated with EGF (50 ng ml21) and lysed at indicated time points. Cell extracts (10 mg protein) were resolved by SDS-PAGE and transferred
to nitrocellulose membranes, which were subjected to western blotting with the indicated antibodies. (b) As in (a), except that uninfected wild-type (WT) MDA-
MB-468 cells or cells infected with retroviruses encoding VHL, FLAG-aNSa1, FLAG-VHL-aNSa1, FLAG-aCS3 and FLAG-VHL-aCS3 were left untreated or treated with EGF
for 30 min prior to lysis. (c) Uninfected (WT) U2OS cells or cells infected with retroviruses encoding VHL, FLAG-aNSa1, FLAG-VHL-aNSa1, FLAG-aCS3 and FLAG-VHL-
aCS3 were transfected with HA-BCR-Abl fusion gene. Cells were treated with or without the BCR-Abl kinase inhibitor Imatinib (1 mM) for 4 h prior to lysis. Cells
were lysed and extracts (10 mg protein) were resolved by SDS-PAGE and transferred to nitrocellulose membranes, which were subjected to western blotting with the
indicated antibodies. (d ) Human erythroleukaemia K-562 cells harbouring the natural BCR-Abl transgene mutation were infected with retroviruses encoding VHL,
FLAG-aNSa1, FLAG-VHL-aNSa1, FLAG-aCS3 and FLAG-VHL-aCS3 or left uninfected (WT). Cells were treated with or without Imatinib (1 mM) for 2 h prior to lysis.
Cells were lysed and extracts (10 mg protein) were resolved by SDS-PAGE and transferred to nitrocellulose membranes, which were subjected to western blotting
with the indicated antibodies.
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loss in phospho-ERK1/2 levels (figure 4b), suggesting that the
effect of SHP099 onMAPK signalling in these cells is mediated,
at least in part, through an off-target mechanism. Interestingly,
SHP099 treatment appeared to cause a slight reduction in
levels of endogenous SHP1 protein (figure 4b).
To mitigate any possibility that the effects of SHP099 on
MAPK signalling in SHP2-depleted U2OS cells were context-
specific, we used the MDA-MB-468 cells that were employed
to demonstrate the allosteric inhibition of SHP2 by SHP099
[21]. In order to explore the effects of SHP099 onMAPK signal-
ling in these cells, we treated wild-type MDA-MB-468 cells or
cells infected with VHL, aCS3 alone or VHL-aCS3 AdPROM
retroviruses, with EGF in the presence or the absence of
SHP099. In wild-type MDA-MB-468 cells, EGF induced a
robust ERK1/2 phosphorylation, while SHP099 completely
blocked this phosphorylation (figure 4c). We observed the
same effects in cells infected with either VHL or aCS3 alone
retroviruses, which did not alter the levels of SHP2 protein
compared with the wild-type controls (figure 4c). In MDA-
MB-468 cells infected with VHL-aCS3, in which no detectable
SHP2 protein levels were observed, EGF still induced robust
ERK1/2 phosphorylation, albeit slightly lower compared with
wild-type control, and SHP099 treatment still resulted in com-
plete inhibition of EGF-induced ERK1/2 phosphorylation
(figure 4c). Given the striking reduction in phospho-ERK1/2
levels caused by SHP099 under conditions where SHP2 protein
levels are undetectable, the effects of SHP099 are likely to be
mediated, at least in part, independently of SHP2 inhibition.
2.5. Comparing proteolytic AdPROM with siRNA for the
depletion of SHP2 protein
In order to evaluate the rate of proteolysis caused by VHL-
aCS3 AdPROM, we packaged VHL-aCS3 into a Tet-inducible
pRetroX-Tight plasmid and introduced it to MDA-MB-468
cells, along with the pRetroX-Tet-On transactivator plasmid.
Treatment of these cells, but not control cells, with doxy-
cycline induced a time-dependent increase in expression of
VHL-aCS3 and a concurrent reduction in SHP2 protein
levels (figure 5a). In cells infected with VHL-aCS3, SHP2
protein levels were substantially reduced at 8 h and almost
completely depleted at 24 h after doxycycline treatment
(figure 5a), suggesting that the expression of VHL-aCS3
induces a rapid degradation of SHP2 protein.
In order to test howAdPROM-mediated SHP2 degradation
compared with siRNA-mediated depletion, we transfected
MDA-MB-468 cells with either control siRNAs or siRNA
pool targeting SHP2 and lysed cells at 8, 24 and 48 h after trans-
fection. As expected, the control siRNAs did not affect the
levels of SHP2 protein at all times tested (figure 5b). By contrast,
siRNAs against SHP2 did not deplete SHP2 protein levels at
8 and 24 h after transfection but caused substantial reduc-
tion in SHP2 levels only 48 h after transfection (figure 5b).
These results clearly demonstrate that siRNA-mediated loss
in target proteins require longer treatments compared with
the proteolytic AdPROM.
2.6. Proteolytic AdPROM is adaptable for degradation
of endogenous ASC
The efficacy of AdPROM-mediated destruction of endo-
genous SHP2 from multiple cell lines prompted us to deploy
the system to explore the efficiency of degradation of other
distinct endogenous proteins, for which selective and potent
nanobodies have been reported. We adapted the proteolytic
AdPROM system by incorporating a nanobody recognizing
the human ASC protein (aASC; figure 6a), in the same way as
we used aNSa1 and aCS3 for SHP2 destruction. VHL-aASC
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Figure 4. Comparing the effects of SHP2 degradation and allosteric inhibition on Ras/MAPK signalling. (a) Human U2OS, A549, K-562 and MDA-MB-468 cells were
treated with DMSO control or 1, 5 and 10 mM SHP099 for 2 h prior to lysis. Extracts (10 mg protein) were resolved by SDS-PAGE and transferred to nitrocellulose
membranes, which were subjected to western blotting with the indicated antibodies. (b) Uninfected U2OS cells (WT) or cells infected with retroviruses encoding VHL,
aCS3 and VHL-aCS3 were treated with or without 5 mM SHP099 for 2 h prior to lysis. Cell extracts (10 mg protein) were resolved by SDS-PAGE and transferred to
nitrocellulose membranes, which were subjected to western blotting with the indicated antibodies. (c) Uninfected MDA-MB-468 cells (WT) or cells infected with
retroviruses encoding VHL, aCS3 or VHL-aCS3 were treated with or without 5 mM SHP099 for 2 h, and stimulated with or without EGF (50 ng ml21) for the last
30 min prior to lysis. Cell extracts (20 mg protein) were processed as described in (b).
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was packaged into mammalian expression pBABE retroviral
vector, with a FLAG-tag at the N-terminus for monitoring
AdPROM expression. We infected ASC-expressing K-562
cells with retroviruses encoding the expression of VHL,
aASC or VHL-aASC and monitored the endogenous ASC
levels (figure 6b). The endogenous ASC levels remained com-
parable and unaltered in uninfected cells and cells infected
with VHL and aASC controls. Strikingly, no detectable
endogenous ASC protein levels were observed in K-562 cells
infected with VHL-aASC, indicating a robust proteolytic
AdPROM system for complete destruction of endogenous
human ASC protein (figure 6b). In order to demonstrate the
affinity of the aASC nanobody for human ASC protein, anti-
FLAG IPs from FLAG-aASC infected cell extracts robustly
precipitated endogenous ASC and depleted it from the
flow-through extracts, while control IPs from uninfected or
FLAG-VHL-infected cell extracts did not (figure 6c). As ASC
was completely degraded by VHL-aASC, IPs of VHL-aASC
did not precipitate detectable levels of ASC protein (figure 6c).
Consistent with the affinity of aASC nanobody only to human
(and notmouse)ASCprotein, theVHL-aASCAdPROM, despite
robust expression, did not degrade endogenous ASC protein in
murine J774 monocytes (figure 6d). Consistent with this, IPs of
aASC and VHL-aASC did not precipitate endogenous ASC
protein from these murine cells (figure 6e). These data suggest
that AdPROM-mediated destruction of human (but not mouse)
ASC protein relies on the affinity of the nanobody to the
human protein. Collectively, our data provide solid evidence
that nanobodies recognizing endogenous target proteins can be
deployed using the proteolytic AdPROM system to achieve
robust degradation of endogenous protein targets in any cell line.
3. Discussion
Efficient targeted proteolysis of endogenous proteins in cells
can serve as a powerful tool to inhibit protein function, both
as a research tool and in therapeutics. In this report, we
describe a robust proteolytic AdPROM system to achieve effec-
tive and efficient destruction of endogenous target proteins,
both constitutively and in an inducible manner. By using
high-affinity polypeptide monobody binders of human SHP2
and a nanobody recognizing human ASC protein conjugated
to the CUL2 substrate receptor VHL,we achieve near-complete
proteolysis of endogenous SHP2 andASC in human cancer cell
lines. We provide evidence that the AdPROM-mediated
proteolysis of endogenous SHP2 requires the CRL-dependent
UPS and can be rescued by the Cullin NEDDylation inhibitor
MLN4924. Furthermore, the expression of the proteolytic
AdPROM in cells does not appear to impact the stability of
the bona fide VHL-target HIF1a.
Gene knockouts are clearly irreversible and for many genes
they are not feasible. Similarly, as we have shown, RNA
interference approaches require long treatments to permit
protein depletion and are also associatedwith off-target effects.
Therefore, rapid and direct destruction of target proteins by the
proteolytic AdPROM system and proteolysis targeting
chimeras (PROTACs) technology, which can overcome these
limitations [12,35], are desirable. We have demonstrated that
proteolytic AdPROM can be applied efficiently for both indu-
cible and constitutive degradation of target proteins [12].While
the development of PROTACs against protein targets can be
extremely tedious and expensive, the proteolytic AdPROM
system can be assembled rapidly and its flexibility makes it
easily adaptable for any number of E3 ubiquitin ligases. The
recent advances in synthetic and antibody-derived monobody
and nanobody technology platforms [13,14] mean that the
portfolio of both monobodies and nanobodies targeting
individual proteins of interest is certain to see an exponential
rise in the near future, thus increasing the target pool for the
proteolytic AdPROM system. Even in the absence of indivi-
dual protein-targeting monobodies and nanobodies, we have
shown how the proteolytic AdPROM system can be applied
relatively quickly, by first generating a GFP knock-in (KI) at
the target loci with CRISPR/Cas9 [12]. The proteolytic
AdPROMsystem can rapidly inform the potential effectiveness
of PROTACs as an approach against specific targets.
By using the VHL-aCS3 AdPROM, we were able to
completely degrade endogenous SHP2 from U2OS, A549,
MDA-MB-231 and MDA-MB-468 cells, and robustly deplete
SHP2 levels from K-562 cells. When compared with control
cells, constitutive SHP2 degradation did not substantially
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Figure 5. Comparing proteolytic AdPROM with siRNA for the depletion of SHP2 protein. (a) MDA-MB-468 cells were infected with retroviruses encoding pRetroX-Tet-
On transactivator and either pRetroX-Tight empty vector or pRetroX-Tight-VHL-aCS3. Infected cells were treated with doxycycline (2 mg ml21) for the indicated time
points prior to lysis. Cell extracts (20 mg protein) were subjected to SDS-PAGE and transferred to PVDF membranes, which were subjected to western blotting with
the indicated antibodies. (b) MDA-MB-468 cells were transfected with non-targeting control siRNAs or siRNAs targeting SHP2 and lysed at the indicated time points
after transfection. Cell extracts (20 mg protein) were subjected to SDS-PAGE and transferred to PVDF membranes, which were subjected to western blotting with the
indicated antibodies.
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alter (A549 and K-562) or only moderately attenuated (U2OS,
MDA-MB-468) the levels of pERK1/2. These observations are
consistent with many reports that imply contrasting context-
specific roles of SHP2 in Ras/MAPK signalling [17,19–21,36].
Recently, a small-molecule allosteric SHP2 inhibitor, SHP099,
was reported to inhibit RTK-dependent Ras/MAPK signall-
ing and cancer cell proliferation in a number of cell lines,
including MDA-MB-468 mammary gland adenocarcinoma
cells [21]. In this study, we too showed that SHP099 potently
inhibited pERK1/2 in MDA-MB-468 cells, as well as U2OS,
A549 and K562 cells. However, the AdPROM-mediated
destruction of SHP2 in MDA-MB-468 and U2OS cells did not
inhibit (or only partially inhibited) pERK1/2 levels. These
observations imply that either the AdPROM-mediated SHP2
depletion, despite resulting in undetectable levels, is still insuf-
ficient to completely block Ras/MAPK signalling or the effect
of SHP099 on Ras/MAPK signalling is mediated, at least
in part, through off-target effects. The SHP2-dependent inhi-
bition of SHP099 on ERK1/2 phosphorylation was in part
bolstered by overexpressing the SHP099-interaction-deficient
mutant of SHP2 (T253M/Q257L) in KYSE520 cells, which
restored the pERK1/2 levels [21]. However, in the light
of our data, and with many other studies reporting contradic-
tory roles of SHP2 on Ras/MAPK signalling as described
above, more work is required to establish the precise, context-
dependent mechanisms of SHP2 action in Ras/MAPK
signalling. The simplicity and broad applicability of the
AdPROM system for complete destruction of SHP2 in many
human cell lines means that it can facilitate rapid investigations
into SHP2 function and substrate identification.
Using the proteolytic AdPROMwith aASC nanobody that
selectively recognizes the human ASC protein, we also
achieved complete destruction of the ASC protein in human
K-562 cells but not in murine J774 cells. These observations
clearly illustrate the affinity-driven nature of the AdPROM
system. The functional tests on the loss of ASC protein from
K-562 cells proved challenging, as these cells were unrespon-
sive to signals that activate the inflammasome signalling
pathway. Nonetheless, AdPROM-mediated destruction of
ASC will be useful for investigating inflammasome signalling
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in relevant contexts, such as monocytes. Consistent with the
notion that affinity is key to proteolysis of the target proteins,
if AdPROM is used with monobodies and nanobodies that
selectively recognize a particular state of the target protein
(e.g. post-translational modification, active or inactive state,
ormutation), then it would be possible, in principle, to degrade
that pool of protein, allowing functional targeting.
With increasing pharmaceutical interest in PROTACs
[37,38], the AdPROM-mediated recruitment and subsequent
ubiquitination of specific target proteins presents a novel and
tantalizing therapeutic opportunity. While PROTACs are
expensive and time-consuming to develop, AdPROM is quick
and robust, and can be exploited as a research tool to explore
the suitability of a protein target as a CRL substrate, prior to
investing time and resources into PROTAC development.
If and when gene delivery technologies become efficient and
routine, AdPROM could be used effectively in therapeutics.
4. Material and methods
4.1. Plasmids and reagents
The cDNAs encoding FLAG-aNSa1 (DU54816), FLAG-VHL-
aNSa1 (DU54843), FLAG-aCS3 (DU54817), FLAG-VHL-aCS3
(DU54844), FLAG-aASC (DU54821), FLAG-VHL-aASC
(DU54832) and human VHL (DU54023) were designed from
published protein sequences [16,17] and cloned into
pBABED-Puro vectors (Cell Biolabs, modified; Dundee-
modified version of the original Cell Biolabs pBABE plasmid)
for constitutive expression. The retroviral expression system
vectors pCMV-Gag-Pol and pCMV-VSVG constructs were
from Clontech. pCDNA5 FRT/TO-HA-BCR-Abl (DU26928)
was transiently expressed in cells where indicated in the
figure legends. All DNA constructs were verified by DNA
sequencing, performed by the DNA Sequencing and Services
(MRCPPU,College of Life Sciences,University ofDundee, Scot-
land, http://www.dnaseq.co.uk) using Applied Biosystems
Big-Dye v. 3.1 chemistry on an Applied Biosystems model
3730 automated capillary DNA sequencer. All constructs are
available to request from the MRC-PPU reagents webpage
(http://mrcppureagents.dundee.ac.uk) and the unique identi-
fier (DU) numbers indicated above provide direct links to the
cloning and sequence details. The pRetroX-Tet-On and pRe-
troX-Tight vectors for inducible AdPROM expression were
obtained from Clontech. The non-targeting control siRNAs
(cat.: D-001810-01-05) and the SHP2 (PTPN11) siRNA pool
(cat.: L-003947-00-0005) were from Dharmacon.
4.2. Antibodies
Rabbit anti-GAPDH (cat.: 2118), anti-SHP2 (C-term) (cat.:
D50F2), anti-SHP2 (N-term) (cat.: 3752), anti-pSHP2 Tyr580
(cat.: 5431), anti-pERK1/2(Thr202/Tyr204) (cat.: 9101), anti-
ERK1/2 (cat.: 4695), anti-pSTAT3 (Tyr705)(cat.: 9131), anti-
STAT3 (cat.: 8768), anti-VHL (cat.: 68547), anti-pSTAT5
(Tyr694) (cat.: 9359) and anti-c-Abl (cat.: 2862) antibodies were
purchased from CST. Anti-HIF1a antibody (cat.: 610959) was
purchased from BD Transduction Laboratories. Anti-FLAG
M2-peroxidase (HRP) (cat.: A8592) was purchased from
Sigma. Anti-phospho-tyrosine (cat.: 05321) antibody was
purchased from Millipore. Anti-ASC antibody (cat.: AL177)
was purchased from Adipogen. For western blot analysis, all
primary antibodies were used at 1 : 1000 dilution, except for
anti-GAPDH antibody, and anti-FLAG M2-peroxidase (HRP),
which were used at 1 : 5000 and 1 : 2000 dilutions, respectively.
Horseradish peroxidase (HRP)-coupled secondary antibodies
(1 : 5000) were obtained from Santa Cruz. Anti-FLAG M2
resin for immunoprecipitation was from Sigma (cat.: A2220).
4.3. Cell culture and lysis
Human U2OS osteosarcoma, A549 pulmonary adenocarcinoma
cells and mouse J774 monocyte were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM; Gibco) supplemented
with 10% (v/v) fetal bovine serum (FBS) (Hyclone), 2 mM
L-glutamine (Lonza), and 1% (v/v) penicillin/streptomycin
(Lonza) and maintained at 378C in a humidified incubator
at 5% CO2. HumanMDA-MB-468 mammary gland adenocarci-
noma, MDA-MB-231 breast cancer and K-562 erythroleukaemia
cellswere cultured inRPMImedium (Gibco) supplementedwith
10%(v/v) fetal bovine serum(FBS) (Hyclone), 2 mML-glutamine
(Lonza) and 1% (v/v) penicillin/streptomycin (Lonza), and
maintained at 378C in a humidified incubator at 5% CO2. Cells
were treated with varying compounds and stimuli as described
in the appropriate figure legends. For retroviral production,
pBABED retroviral plasmids (6 mg) encoding appropriate pro-
teins were co-transfected with pCMV-gag-pol (3.2 mg) and
pCMV-VSV-G (2.8 mg) in a 10 cm–diameter dish of 70% conflu-
ent 293-FT cells. In short, plasmids were mixed in 600 ml
Opti-MEM Reduced Serum Medium (Life Technologies) to
which 24 ml of 1 mg ml21 polyethylenimine (PEI) (Polysciences
Inc.) diluted in 25 mM HEPES pH 7.5 was added. Following
20 s of vortexing and incubation for 20 min at room temperature,
the resulting transfection solution was applied drop-wise to the
293-FT cells. The medium was replaced 16 h post-transfection
with fresh fullmedium, followed by collection of the retroviruses
in the growth medium 24 h later, which were filtered using
0.45 mmfilters. Target cells (approx. 60%confluent)were infected
with the optimized titre of retroviral medium containing
8 mg ml21 polybrene (Sigma) for 24 h, as described previously
[12,39,40].Cellswhichhad integrated the retroviruswere selected
with 2 mg ml21 puromycin thereafter.
For lysis, cells were washed twice in ice-cold phosphate-
buffered saline (PBS), scraped on ice in lysis buffer (50 mM
Tris–HCl pH 7.5, 0.27 M sucrose, 150 mMNaCl, 1 mM EGTA,
1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium
b-glycerophosphate, 50 mM sodium fluoride, 5 mM sodium
pyrophosphate, 1% (v/v) Nonidet P-40) supplemented with
complete protease inhibitors (one tablet per 25 ml; Roche) and
0.1% (v/v) b-mercaptoethanol (Sigma). Cell extracts were clari-
fied and either processed immediately or snap-frozen in liquid
nitrogen prior to storage at 2808C. The protein concentration
was determined in a 96-well format using Bradford protein
assay reagent (Pierce). Foranti-FLAGM2 immunoprecipitation,
lysates (typically 1 mg) were incubated with anti-FLAG M2
resin (10 ml) for 16 h overnight at 48C on a rotating wheel.
Following washing of the resin with lysis buffer 3, FLAG-
fusion proteins were eluted from the resin by boiling for 5 min
at 958C in 1 SDS sample buffer. Samples were then processed
for SDS-PAGE as described above.
4.4. Growth factors and small-molecule inhibitors
Purified recombinant human epidermal growth factor
(EGF) was purchased from R&D Systems (cat.: 236-EG) and
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reconstituted in sterile phosphate-buffered saline (PBS). Cells
were serum-deprived for approximately 16 h prior to stimu-
lation with 50 ng ml21 EGF for the indicated durations.
Imatinib mesylate (Gleevec) was obtained from LC Labora-
tories (cat.: I-5508) and reconstituted at 10 mM stock in
dimethyl sulfoxide (DMSO). Cells were incubated with 1 mM
Imatinib (or equivalent volume of DMSO) for 4 h (U2OS cells)
or 2 h (K-562 cells) in serum-free DMEM prior to cell lysis.
SHP099 (hydrochloride)waspurchased fromMedChemExpress
(cat.: HY-100388A) and reconstituted at 10 mM in DMSO. Cells
were incubated with the indicated concentration of SHP099 (or
equivalent volume of DMSO) in serum-free DMEM for 2 h
prior to cell lysis. MLN4924 was from Active Biochem (cat.:
A-1139) and was reconstituted at 1mM in DMSO.
4.5. SDS-PAGE and western blotting
Reduced protein extracts (typically 10–20 mg protein unless
stated otherwise) or immunoprecipitates (IPs) were separated
on 8% SDS-PAGE gels, or NuPAGE 4–12% Bis-Tris protein
gels (Invitrogen) by electrophoresis. Subsequently, proteins
were transferred onto polyvinylidene fluoride (PVDF) (Milli-
pore) or nitrocellulose membranes (Amersham), prior to
blocking in 5% (w/v) non-fat milk (Marvel) in TBS-T (50 mM
Tris–HCl pH 7.5, 150 mMNaCl, 0.2% Tween-20). Membranes
were incubated overnight at 48C in 5% (w/v) bovine serum
albumin (BSA)-TBS-T or 5% (w/v) milk-TBS-Twith the appro-
priate primary antibodies. Membranes were subsequently
washed in TBS-T and incubated with HRP-conjugated second-
ary antibodies in 5% (w/v) milk-TBS-T for 1 h at RT.
Membranes were subjected to further washing in TBS-T,
prior to detection using enhanced chemiluminescence (ECL)
reagent (Thermo Scientific) and exposure on medical X-ray
films (Konica Minolta) as described previously [12,41].
4.6. RNA-isolation, cDNA synthesis and RT-PCR
Cells were washed in PBS and harvested using standard pro-
cedures. RNA was isolated following the manufacturer’s
guidelines (Qiagen). cDNA synthesis and RT-PCR were per-
formed as described previously [39,42]. SHP2 (forward:
GACGGCAAGTCTAAAGTGAC; reverse: GCTTTCTATTTC
AGCAGCAT) and GAPDH (forward: TGCACCACCAAC
TGCTTAGC; reverse: GGCATGGACTGTGGTCATGAG) pri-
mers were from Invitrogen. Statistical analysis was performed
using Student’s t-test on data obtained from three independent
biological replicates. A p-value of less than 0.05 was deemed
significant.
4.7. siRNA transfection
Cells were transfected with 20 nM (final) small interfering
RNA (siRNA) oligonucleotides using 4 ml Lipofectamine
RNAiMAX (Invitrogen) transfection reagent per well in a 6-
well cell culture plate, in a final volume of 1 ml Optimem
(Gibco). Cells were lysed at 8 h, 24 h and 48 h post-transfection.
For the 24 and 48 h time points, the transfection medium was
replaced by fresh growth medium after 16 h post-transfection.
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